Cargando…

A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09

PURPOSE: Pegylated granulocyte-colony-stimulating factor (G-CSF) is frequently used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy with a high risk of myelosuppression. This phase II/III study was conducted to determine the adequate dose of pegteograstim, a new formulation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ki Hyeong, Kim, Ji-Yeon, Lee, Moon Hee, Han, Hye Sook, Lim, Joo Han, Park, Keon Uk, Park, In Hae, Cho, Eun Kyung, Yoon, So Young, Kim, Jee Hyun, Choi, In Sil, Park, Jae Hoo, Choi, Young Jin, Kim, Hee-Jun, Jung, Kyung Hae, Kim, Si-Young, Oh, Do-Youn, Im, Seock-Ah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766213/ https://www.ncbi.nlm.nih.gov/pubmed/26423618 http://dx.doi.org/10.1007/s00520-015-2963-7

Ejemplares similares

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
por: Kang, Ka‐Won, et al.
Publicado: (2020)

Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
por: Lee, Jieun, et al.
Publicado: (2023)

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
por: Lee, Jiyun, et al.
Publicado: (2021)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
por: Lee, Soohyeon, et al.
Publicado: (2020)

Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
por: Moon, Yong Wha, et al.
Publicado: (2023)

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
por: Kim, Seung Tae, et al.
Publicado: (2022)

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
por: Park, In Hae, et al.
Publicado: (2019)

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
por: Lee, Dae-Won, et al.
Publicado: (2023)

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
por: Choi, Yoon Ji, et al.
Publicado: (2018)

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
por: Kim, Ji-Yeon, et al.
Publicado: (2019)

Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg®) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial
por: Park, Kwonoh, et al.
Publicado: (2023)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
por: Sim, Sung Hoon, et al.
Publicado: (2022)

Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
por: Jung, Hyun Ae, et al.
Publicado: (2022)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
por: Lee, Jihyoun, et al.
Publicado: (2018)

A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
por: Kim, Gun Min, et al.
Publicado: (2019)

Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study
por: Jeon, Youngwoo, et al.
Publicado: (2023)

Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
por: Kang, Eun Joo, et al.
Publicado: (2022)

Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2023)

COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim
por: Gwak, Hongki, et al.
Publicado: (2022)

An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer
por: Lee, Anbok, et al.
Publicado: (2023)

Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)
por: Kim, Jung Sun, et al.
Publicado: (2023)

Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06
por: Sohn, Byeong Seok, et al.
Publicado: (2023)

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2020)

Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2022)

A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)
por: Lee, Keun-Wook, et al.
Publicado: (2023)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
por: Kim, Se Hyun, et al.
Publicado: (2016)

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
por: Yoon, Shinkyo, et al.
Publicado: (2022)

Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
por: Kim, Do Young, et al.
Publicado: (2022)

ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
por: Yoon, Shinkyo, et al.
Publicado: (2023)

APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia
por: Kim, Hyery, et al.
Publicado: (2018)

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
por: Jeong, Seong Hyun, et al.
Publicado: (2022)

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lee, Soohyeon, et al.
Publicado: (2022)

Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
por: Kim, Jung Sun, et al.
Publicado: (2023)

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07
por: Kim, Miso, et al.
Publicado: (2020)

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
por: Han, Hye Sook, et al.
Publicado: (2021)

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
por: Yoo, Kwai Han, et al.
Publicado: (2019)

Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study
por: Wang, Ching-Yu, et al.
Publicado: (2023)

Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node‐positive bladder cancer: A retrospective analysis: KCSG GU 17‐03
por: Bae, Woo Kyun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_91nmj0dmgekeokaas0erfb5u1b